News

Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, which is administered by subcutaneous injection in combination with intravenous (IV) chemotherapy. Phesgo is said

Adult patients with transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response or are ineligible for erythropoietin-based

Piramal Pharma comprises four businesses, which includes a contract development and manufacturing (CDMO) business called Piramal Pharma Solutions. The pharma group also runs a complex hospital generics business

The company expects to complete the NDA submission in the 4th quarter of 2020. “Following receipt of Breakthrough Therapy, Fast Track, and Orphan Designations, the initiation of the

Theravance is considering that the TD-0903 can block the cytokine storm linked with ALI and prevent progression to acute respiratory distress syndrome (ARDS). According to the company, the

According to the Australian clinical-stage pharma company, Veyonda has been designed to inhibit cGAS-STING signalling. The drug candidate is being developed as a potential treatment of cytokine storm

As part of the agreement, Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support

Compared with glycopyrronium/formoterol fumarate, PT010 achieved a 24% reduction (p<0.001) in exacerbations. PT010 achieved a 13% reduction (p=0.003) compared with PT009 (budesonide/formoterol fumarate). The dual-combination therapies used as

Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply. The agreement follows AstraZeneca’s recent announcement of a